Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Reck, Martin; Karagiannis, Tom; Wehler, Thomas; Shtivelband, Mikhail; Gonzalez-Larriba, Jose-Luis; Rothenstein, Jeffrey; Frueh, Martin; Deng, Yu; Lopez-Chavez, Ariel; Sandler, Alan; Socinski, Mark A.

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15